| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 4, 2002
Accepted on March 25, 2002
From the Division of Epidemiology (A.R.F., L.W.), School of Public Health, University of Minnesota, Minneapolis; the Division of Hematology (N.A., K.K.W.), University of Texas Medical School, Houston; the Department of Medicine (M.C.), University of Vermont, Burlington; and the Division of General Medicine (R.H.W.), University of California-Davis, Sacramento.
* To whom correspondence should be addressed. E-mail: folsom{at}epi.umn.edu.
AbstractAlthough
deficiencies of protein C and antithrombin, 2 natural plasma
anticoagulants, are known risk factors for venous thrombosis,
population-based prospective incidence data on these associations are
lacking. Venous thromboembolic events have been identified in adults in
2 longitudinal cohort studies, the Atherosclerosis Risk
in Communities (ARIC) Study and the Cardiovascular
Health Study (CHS). Incidence was examined in relation to
prediagnostic plasma levels of protein C (ARIC Study only)
and antithrombin. Over a mean of 8.1 years of follow-up, there were 130
incident venous thromboembolic events that were not due to cancer in
the ARIC Study. The age-adjusted incidence was elevated 3.36-fold (95%
CI 1.24 to 9.11) in the 1.1% of subjects with protein C values <2.0
mg/L compared with subjects with higher values. In contrast, in the
ARIC Study and the CHS, there was no association between low plasma
antithrombin and venous thromboembolism. In conclusion, in this
population-based study, a low protein C, but not antithrombin, level
has been determined to be associated with an increased incidence of
venous thromboembolism. Attributable risk estimates suggest that low
protein C levels account for
2.5% of venous thromboembolic events
in the ARIC
population.
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |